(NASDAQ: INKT) Mink Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.9%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.76%.
Mink Therapeutics's earnings in 2026 is -$11,024,955.On average, 4 Wall Street analysts forecast INKT's earnings for 2026 to be -$11,546,081, with the lowest INKT earnings forecast at -$12,476,811, and the highest INKT earnings forecast at -$10,403,332. On average, 4 Wall Street analysts forecast INKT's earnings for 2027 to be -$8,194,838, with the lowest INKT earnings forecast at -$12,124,643, and the highest INKT earnings forecast at -$3,881,036.
In 2028, INKT is forecast to generate -$12,174,439 in earnings, with the lowest earnings forecast at -$12,024,023 and the highest earnings forecast at -$12,182,140.